United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - parathyroid hormone (unii: n19a0t0e5j) (parathyroid hormone - unii:n19a0t0e5j) - parathyroid hormone 25 ug in 0.08 ml - natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin d to control hypocalcemia in patients with hypoparathyroidism. limitations of use - because of the potential risk of osteosarcoma, natpara is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin d alone [see warnings and precautions (5.1)] . - natpara was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. - natpara was not studied in patients with acute post-surgical hypoparathyroidism. natpara is contraindicated in patients with a known hypersensitivity to any component of this product. hypersensitivity reactions (e.g., anaphylaxis, angioedema, and urticaria) have occurred with natpara [see warnings and precautions (5.6), adverse reactions (6.3)] . risk summary available data with natpara injection use in pregnant women are insufficient to inform a drug associated risk of birth defects, miscarriage or adverse maternal or fetal out

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals - thyroid, porcine (unii: 6rv024oauq) (sus scrofa thyroid - unii:6rv024oauq) - thyroid, porcine 120 mg - armour thyroid tablets are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (seewarnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic iymphocytic thyroiditis (hashimoto's), multinodular goiter, and in the management of thyroid cancer. thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrecte

United States - English - NLM (National Library of Medicine)

true botanica, llc - thyroid, bovine (unii: mn18otn73w) (thyroid, bovine - unii:mn18otn73w) - thyroid, bovine 6 [hp_x] in 23 g - enter section text here supports normal functions of the thyroid gland. may also be used for standard homeopathic indications or as directed by your physician. tamper evident: do not use if safety seal is broken before first use.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have

United States - English - NLM (National Library of Medicine)

athenex pharmaceutical division, llc. - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established. caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating. studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities. therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of non-treatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema have not been reported in the literature. however, patients should be treated with levothyroxine sodium for injection as the risk of non-treatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. adequate replacement doses of thyroid hormones are required to maintain normal lactation. there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who are lactating. however, such patients should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the nursing patient. myxedema coma is a disease of the elderly. an approved, oral dosage form of levothyroxine should be used in the pediatric patient population for maintaining a euthyroid state in non-complicated hypothyroidism. see section 2, dosage and administration, for full prescribing information in the geriatric patient population. because of the increased prevalence of cardiovascular disease in the elderly, cautious use of levothyroxine sodium for injection in the elderly and in patients with known cardiac risk factors is advised. atrial fibrillation is a common side effect associated with levothyroxine treatment in the elderly [see dosage and administration ( 2) and warnings and precautions ( 5)].

United States - English - NLM (National Library of Medicine)

maia pharmaceuticals, inc. - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium for injection is indicated for the treatment of myxedema coma. important limitations of use: the relative bioavailability between levothyroxine sodium for injection and oral levothyroxine products has not been established.  caution should be used when switching patients from oral levothyroxine products to levothyroxine sodium for injection as accurate dosing conversion has not been studied. none. pregnancy category a – there are no reported cases of levothyroxine sodium for injection used to treat myxedema coma in patients who were pregnant or lactating.  studies in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not shown an increased risk of fetal abnormalities.  therefore, pregnant patients who develop myxedema should be treated with levothyroxine sodium for injection as the risk of nontreatment is associated with a high probability of significant morbidity or mortality to the maternal patient and the fetus. patients in labor who develop myxedema hav

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium injection is indicated for the treatment of myxedema coma. limitations of use: not recommended as a substitute for oral levothyroxine sodium because the relative bioavailability of levothyroxine sodium injection to oral levothyroxine sodium has not been established and there is a risk of inaccurate dose conversion. uncorrected adrenal insufficiency [see warnings and precautions (5.2)] risk summary there is no available data with use of levothyroxine sodium injection in pregnant women. the clinical data in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not reported increased rates of major birth defects, miscarriages, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with myxedema coma in pregnancy (see clinical considerations) . animal reproduction studies have not been conducted with levothyroxine sodium. the estimated background risk of major birth defects and miscarriage for the indicated populatio

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium injection is indicated for the treatment of myxedema coma. limitations of use: not recommended as a substitute for oral levothyroxine sodium because the relative bioavailability of levothyroxine sodium injection to oral levothyroxine sodium has not been established and there is a risk of inaccurate dose conversion. uncorrected adrenal insufficiency [see warnings and precautions (5.2)] risk summary there is no available data with use of levothyroxine sodium injection in pregnant women. the clinical data in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not reported increased rates of major birth defects, miscarriages, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with myxedema coma in pregnancy (see clinical considerations) . animal reproduction studies have not been conducted with levothyroxine sodium. the estimated background risk of major birth defects and miscarriage for the indicated populatio

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium injection is indicated for the treatment of myxedema coma. limitations of use: not recommended as a substitute for oral levothyroxine sodium because the relative bioavailability of levothyroxine sodium injection to oral levothyroxine sodium has not been established and there is a risk of inaccurate dose conversion. uncorrected adrenal insufficiency [see warnings and precautions (5.2)] risk summary there is no available data with use of levothyroxine sodium injection in pregnant women. the clinical data in pregnant women treated with oral levothyroxine to maintain a euthyroid state have not reported increased rates of major birth defects, miscarriages, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with myxedema coma in pregnancy (see clinical considerations) . animal reproduction studies have not been conducted with levothyroxine sodium. the estimated background risk of major birth defects and miscarriage for the indicated populatio

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - liothyronine sodium (unii: gca9vv7d2n) (liothyronine - unii:06lu7c9h1v) - thyroid hormone drugs are indicated: - as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see warnings ). - as pituitary thyroid-stimulating hormone (tsh) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (hashimoto’s) and multinodular goiter. - as diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism